Lengthening of Q-Tinterval in isoniazid treatment (case report and review of literature)

Lengthening of Q-Tinterval in isoniazid treatment (case report and review of literature)

Bibliographic Details
Main Authors:	L M Makarov, S N Chuprova, R Sh Garipov, E V Sorokina, E В Polyakova, L A Kalinin
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2003-12-01
Series:	Терапевтический архив
Subjects:	clinical notes tuberculosis treatment isoniazide electrocardiogram
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/29712

Similar Items

ISONIAZID - MONORESISTANT TUBERCULOSIS IN BULGARIA
by: Stanislava Yordanova, et al.
Published: (2020-05-01)

Formulation of dispersible isoniazid/pyridoxine fixed-dose combination tablets for isoniazid preventive therapy in pediatrics
by: M. W. Mwangi, et al.
Published: (2020-01-01)

Severe isoniazid related sideroblastic anemia
by: Rein Jan Piso, et al.
Published: (2011-01-01)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
by: Byung Woo Jhun, M.D., et al.
Published: (2020-01-01)

Isoniazid, The Frontline of Resistance in Mycobacterium tuberculosis
by: James B. Whitney, et al.
Published: (2002-12-01)

Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis
by: Seo W, et al.
Published: (2023-08-01)

Status of contact screening and isoniazid preventive therapy for children under age six in Puducherry district, under the Revised National Tuberculosis Control Programme: An operational research
by: Ariarathinam Newtonraj, et al.
Published: (2020-01-01)

Molecular characterization of Mycobacterium tuberculosis strains resistant to isoniazid
by: Salma Smaoui, et al.
Published: (2016-01-01)

Complication of Mycobacterium tuberculosis treatment: Isoniazid-induced pneumonitis
by: Brian Cody Adkinson, et al.
Published: (2020-11-01)

Phenotypic low-level isoniazid resistance as a marker to predict ethionamide resistance in Mycobacterium tuberculosis
by: Salima Qamar, et al.
Published: (2017-01-01)

Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles
by: Kalaiselvi Kumarasingam, et al.
Published: (2018-01-01)

Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia
by: Wira Winardi, et al.
Published: (2022-09-01)

CURRENT APPROACHES TO CONTROL OF ISONIAZID-RESISTANT TUBERCULOSIS
by: Vladimir Milanov, et al.
Published: (2022-10-01)

NAT2 Genotype and Isoniazid Medication in Children
by: Klaus Golka, et al.
Published: (2016-09-01)

Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid
by: Konrad Juszkiewicz, et al.
Published: (2019-09-01)

Drug Resistance in Mycobacterium Tuberculosis Isolates to Isoniazid and Rifampin
by: M Pourhajibagher, et al.
Published: (2012-05-01)

Hyperglycaemia induced by isoniazid preventive therapy
by: Roshni Jhan Ganguly, et al.
Published: (2018-01-01)

Pharmacokinetics of isoniazid in Wistar rats exposed to ethanol
by: Taísa Busaranho Franchin, et al.
Published: (2023-01-01)

Isoniazid-induced flu-like syndrome: A rare side effect
by: Sudipta Pandit, et al.
Published: (2013-01-01)

Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
by: Beuy Joob, et al.
Published: (2021-01-01)

Apoptosis and Phagocytosis Activity of Macrophages Infected by Mycobacterium tuberculosis Resistant and Sensitive Isoniazid Clinical Isolates
by: Farida J. Rachmawaty, et al.
Published: (2006-06-01)

Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis
by: I Frésard, et al.
Published: (2011-08-01)

Isoniazid metabolism and hepatotoxicity
by: Pengcheng Wang, et al.
Published: (2016-09-01)

Highly Sensitive Detection of Isoniazid Heteroresistance in Mycobacterium Tuberculosis by Droplet Digital PCR
by: Zheng Y, et al.
Published: (2022-10-01)

Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania
by: Olivia F. Hunter, et al.
Published: (2020-10-01)

Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
by: Marwa Bachir, et al.
Published: (2021-06-01)

A retrospective cohort study of isoniazid-resistant tuberculosis treatment outcomes and isoniazid resistance-associated mutations in eastern China from 2013 to 2018
by: Yan Shao, et al.
Published: (2020-09-01)

Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
by: Phan Vuong Khac Thai, et al.
Published: (2018-03-01)

Contribution of putative efflux pump genes to isoniazid resistance in clinical isolates of Mycobacterium tuberculosis
by: Anshika Narang, et al.
Published: (2017-01-01)

Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery
by: Franklin Afinjuomo, et al.
Published: (2019-10-01)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in <it>Mycobacterium tuberculosis</it>
by: Parsons Linda M, et al.
Published: (2001-04-01)

Isoniazid-induced gynaecomastia: report of a paediatric case and review of literature
by: Sarah Wing Yiu Poon, et al.
Published: (2020-10-01)

Evidenziazione molecolare di resistenza di Mycobacterium tuberculosis complex a rifampicina e isoniazide
by: Gian Lorenzo Molinari, et al.
Published: (2006-06-01)

Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017–2019
by: Emmanuel Ssendikwanawa, et al.
Published: (2023-05-01)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
by: Wendy A. Lai, et al.
Published: (2022-12-01)

Assessment of adherence to antituberculosis drug regimen among patients receiving isoniazid, rifampin and pyrazinamide: Kerman, Iran
by: Seyyed Mojtaba Sohrevardi, et al.
Published: (2019-07-01)

Electrospun Orodispersible Films of Isoniazid for Pediatric Tuberculosis Treatment
by: Konstantina Chachlioutaki, et al.
Published: (2020-05-01)

Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand
by: Ajala Prommi, et al.
Published: (2024-03-01)

In vitro anti-mycobacterial activity of (E)-N´-(monosubstituted-benzylidene) isonicotinohydrazide derivatives against isoniazid-resistant strains
by: Tatiane S. Coelho, et al.
Published: (2012-02-01)

Isoniazid- and ethambutol-induced psychosis
by: Prasad R, et al.
Published: (2008-01-01)